Trials / Recruiting
RecruitingNCT06666270
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of SYN818, a DNA Polymerase Theta (POLQ) Inhibitor Alone in Patients With Locally Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
Detailed description
This study is a Phase I, open-label, multicentre study of SYN818 administered orally in patients with advanced solid tumors
Conditions
- Advanced Solid Cancer
- Metastatic Solid Tumor
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- BRCA Mutation
- HRR Deficiency
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYN818 | Patients will orally receive SYN818 |
Timeline
- Start date
- 2024-11-21
- Primary completion
- 2026-06-30
- Completion
- 2026-12-30
- First posted
- 2024-10-30
- Last updated
- 2025-07-20
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06666270. Inclusion in this directory is not an endorsement.